Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (Nasdaq: BCAB) is a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, and its news flow reflects the progress of this platform. Company announcements regularly describe updates on CAB-based antibody-drug conjugates and bispecific T-cell engagers, regulatory interactions, financing arrangements, and strategic collaborations.
Recent BioAtla news has highlighted the clinical and regulatory path for ozuriftamab vedotin (Oz-V), a CAB-Platform ROR2-targeting ADC. Releases describe compelling Phase 2 data in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), FDA Fast Track Designation for certain squamous cell carcinoma of the head and neck patients, and FDA alignment on a randomized Phase 3 trial design with dual primary endpoints. Additional coverage explains a special purpose vehicle (SPV) transaction with Inversagen AI, LLC and GATC Health Corp. intended to fund a registrational Oz-V trial in OPSCC while BioAtla retains a majority ownership interest in the Oz-V asset.
News items also focus on mecbotamab vedotin (Mec-V), a CAB AXL-targeting ADC in Phase 2 development, including clinical data in treatment-refractory soft tissue sarcomas and mKRAS non-small cell lung cancer. For BA3182, a CAB EpCAM x CAB CD3 bispecific T-cell engager, BioAtla has reported preliminary Phase 1 results in metastatic adenocarcinoma patients, describing a manageable safety profile and prolonged tumor control at higher dose levels.
Investors following BCAB news will also see regular updates on financial results, cash runway, and capital structure. The company has announced Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide flexible equity-linked financing, as well as a special meeting of stockholders to consider approval of potential share issuances and a possible reverse stock split. Additional releases discuss Nasdaq listing compliance milestones, patent coverage, and licensing agreements such as the worldwide license to Context Therapeutics for a CAB Nectin-4 x CD3 T-cell engager.
For those tracking oncology pipelines, regulatory milestones, and financing developments in clinical-stage biotech, the BioAtla news page offers ongoing detail on how the CAB platform and its lead programs are progressing. Investors and observers can use this stream of press releases to monitor trial design decisions, data presentations at major medical congresses, partnership activity and key corporate events related to BCAB stock.
BioAtla (Nasdaq: BCAB) and GATC Health announced a $40 million SPV financing to advance ozuriftamab vedotin (Oz-V) into a registrational Phase 3 trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC).
BioAtla will receive an initial $5 million at closing and expects the remaining $35 million in Q1 2026; BioAtla will retain 65% ownership of Oz-V while Inversagen AI will hold 35%. BioAtla will lead Phase 3 execution with enrollment anticipated to begin in early 2026 and a data path toward potential accelerated approval in the US.
BioAtla (Nasdaq: BCAB) entered agreements providing flexible financing totaling up to $22.5 million to support operations while finalizing a strategic partnership. BioAtla received a $7.125 million gross cash advance under Pre-paid Advance Agreements for $7.5 million face value, which accrues 4% interest and may be repaid in cash or converted into common stock at the lower of $1.39 or 95% of the lowest daily VWAP during a specified look-back. Yorkville committed up to $15 million under a Standby Equity Purchase Agreement to buy common stock at a 3% discount over three years if the company exercises its option. Tungsten Advisors acted as placement agent.
BioAtla (Nasdaq: BCAB) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company achieved FDA alignment on a planned randomized Phase 3 Oz-V trial in 2L+ OPSCC with dual primary endpoints (overall response rate and overall survival) and potential accelerated approval. BA3182 (CAB-EpCAM x CAB-CD3-TCE) dose escalation showed a confirmed partial response ongoing >6 months and a Phase 1 readout is expected in H1 2026. Mecbotamab vedotin (Mec-V) showed median OS 21.5 months in 44 evaluable soft tissue sarcoma patients. Q3 results: R&D $9.5M, G&A $4.2M, net loss $15.8M, cash $8.3M and a recent $2.0M milestone payment.
BioAtla (Nasdaq: BCAB) reported that mecbotamab vedotin (Mec-V), an AXL-targeting CAB ADC, achieved a median overall survival (OS) of 21.5 months in a 44-patient subset with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, versus ~12 months with approved agents.
Data (cutoff March 25, 2025) show median OS 22.9 months in the combination arm and 18.4 months in monotherapy; 12-month OS rate 73%; disease control rate 52%; two partial responses reported. Safety was manageable with no treatment-related deaths; grade 3/4 neutropenia 21% and transaminase elevations 16%.
BioAtla (Nasdaq: BCAB) will announce its third quarter 2025 financial results and provide business highlights on Thursday, November 13, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results for the quarter ended September 30, 2025. Investors can access the live webcast via the company website and dial in domestically at (800) 343-4136 or internationally at (203) 518-9843 using Conference ID BIOATLA.
The press release with financial results will be posted in News Releases prior to the call, and a replay will be available under Events & Presentations in the Investors section of the website.
BioAtla (NASDAQ: BCAB) will present a poster at the International Papillomavirus Society Conference in Bangkok (Oct 23–26, 2025) detailing mechanistic rationale and clinical data for its ADC ozuriftamab vedotin (Oz-V) targeting ROR2 in advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC). The poster, titled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma,” will be presented on Oct 25, 2025 during E-Poster 02 (6:30–8:00 PM ICT). The presentation provides a molecular review of CAB-ROR2-ADC, discusses ROR2 expression linked to HPV infection, and highlights clinical data previously shown at medical congresses. Presentation materials will be posted in the company’s Publications section at www.bioatla.com after the session concludes.
BioAtla (Nasdaq: BCAB) reported preliminary Phase 1 results for BA3182, a dual‑conditionally binding EpCAM x CD3 bispecific T‑cell engager, presented at ESMO 2025 (Oct 19, 2025). In a 35‑patient, heavily pretreated cohort (median 3 prior lines), BA3182 showed a confirmed partial response (cPR) at 0.6 mg in intrahepatic cholangiocarcinoma with >6 months without progression and prolonged tumor control at doses ≥0.6 mg. Safety was manageable: only 2 cytokine release syndrome events and reversible, transient liver analyte elevations; dose escalation continues and the maximally tolerated dose is not yet defined.
BioAtla (NASDAQ: BCAB) announced clinical data for its AXL-targeting ADC mecbotamab vedotin (BA3011) will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, Nov 5-9, 2025, at National Harbor, MD.
The presentation by Dr. Mihaela Druta on Nov 7, 2025 reports a median overall survival (OS) of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma (abstract #523). Poster session timing to be announced; slides will be posted in the company Publication section after the presentation.
BioAtla (NASDAQ:BCAB) has received FDA alignment on the Phase 3 trial design for ozuriftamab vedotin (Oz-V) in treating Oropharyngeal Squamous Cell Carcinoma (OPSCC). The trial will involve approximately 300 patients randomized between Oz-V and investigator's choice of standard treatments.
The company's Phase 2 trial demonstrated promising results with an overall response rate of 45% and median overall survival of 11.6 months, significantly outperforming current treatments which show only 0-3.4% response rates and 4.4 months median survival. The Phase 3 study design includes potential for accelerated approval based on response rate improvements, with full approval contingent on overall survival benefits.
BioAtla plans to initiate the Phase 3 study with a strategic partner in early 2026 and maintains guidance for completing a strategic partnership for one of its advanced clinical assets this year.
BioAtla (NASDAQ:BCAB) reported Q2 2025 financial results and clinical progress updates. The company's Phase 1 CAB-EpCAM x CAB-CD3 bispecific T-cell engager (BA3182) showed promising results with seven patients achieving tumor size reductions ranging from -5% to -25%. Their Fast Track Designated ozuriftamab vedotin (Oz-V) demonstrated strong efficacy in HPV+ head and neck cancer with a 45% overall response rate and 100% disease control rate.
Financial results showed R&D expenses decreased to $13.7M from $16.2M year-over-year, while net loss improved to $18.7M from $21.1M. The company ended Q2 with $18.2M in cash, down from $49.0M at 2024 year-end, and expects decreased quarterly cash burn as Phase 2 trials conclude. BioAtla remains confident in closing at least one partnership transaction in 2025.
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
